SCHEMBL30808296

SCHEMBL30808296

CCCCCc1nc(N)c(N)c(Cl)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 3/20 0.40
▸ ADORA2B P29275 2/20 0.40
▸ ADORA1 P30542 2/20 0.40
▸ ADORA3 P0DMS8 1/20 0.40
▸ TLR8 Q9NR97 3/20 0.35
▸ MAPT P10636 2/20 0.35
▸ ATM Q13315 2/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ CASP1 P29466 1/20 0.34
▸ TLR7 Q9NYK1 3/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ PI4KA P42356 1/20 0.33
▸ PI4K2B Q8TCG2 1/20 0.33
▸ PI4K2A Q9BTU6 1/20 0.33
▸ PI4KB Q9UBF8 1/20 0.33
▸ DHFR P00374 1/20 0.33
▸ GPR84 Q9NQS5 1/20 0.33
▸ KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19714688 0.86 CASP1 (0.46) CASP1
SCHEMBL19714665 0.82 CASP1 (0.33) CASP1
SCHEMBL1003303 0.78 ADORA1 (0.33) ADORA1LMNAALDH1A1DHFRKCNH2
SCHEMBL11569832 0.76 ADORA2A (0.40) ADORA2AADORA2BADORA1ADORA3TLR8
SCHEMBL11572610 0.76 ADORA2A (0.40) ADORA2AADORA2BADORA1ADORA3TLR8
SCHEMBL28462770 0.72 CASP1 (0.39) CASP1
SCHEMBL92739 0.72 KCNH2 (0.46) ADORA2AADORA2BADORA1ADORA3L3MBTL1
SCHEMBL8647469 0.72 CASP1 (0.50) ADORA2AADORA2BADORA1ADORA3TLR8
SCHEMBL447214 0.71 KMT2A (0.42) ADORA2AADORA2BADORA1ADORA3LMNA
SCHEMBL1543072 0.71 KMT2A (0.42) ADORA2AADORA2BADORA1ADORA3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113039182-B Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment 伊文蒂瓦公司 2024-02-20 — — CN disclosed
Send feedback